Cell Therapy Associated With Endobronchial Valve

Status Recruiting

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is one of the most common diseases worldwide and is considered a public health problem. The World Health Organization estimates that about 210 million people have COPD. Disease-related mortality is more than 3 million, representing 5% of all deaths, 90% of this mortality being concentrated in middle- and low-income countries. COPD can be subdivided into chronic bronchitis and emphysema. Emphysema, the focus of this project, is histologically defined by the permanent increase of the distal air spaces to the terminal bronchioles associated with the destruction of the alveolar septa in the lung. Approximately two-thirds of adult men and a quarter of women (most without dysfunction) will have well-defined emphysema, but often of limited extent. Mesenchymal stem cells (MSCs) have anti-inflammatory, anti-fibrotic, microbicide and repair potential. Regarding COPD, several authors have concentrated efforts in the investigation of the relationship between the severity of the condition and the various sources of adult stem cells. Apparently the lungs have a high chemotactic effect in relation to adult stem cells, since several studies have evidenced a high implantation (6-20%) of stem cells derived from bone marrow, administered systemically, in the pulmonary tissue of receptors. Therefore, MSCs has been tested in different lung diseases have no effective treatment, such as pulmonary fibrosis, acute respiratory distress syndrome, asthma, COPD positive results, such as reduction of fibrosis, reduction of proliferation inflammatory cells and cytokines, reduction of infectious processes and recovery of the histological changes caused by pulmonary emphysema. Based on these findings, the purpose of this project is to evaluate the safety and efficacy of endoscopic administration of bone marrow stem cells in patients with severe homogeneous emphysema and evaluating the feasibility, efficacy and safety of this procedure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Obstructive Pulmonary Disease Severe
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive

Clinical Trial Details

NCT number	NCT04018729
Study type	Interventional
Source	Hospital de Clinicas de Porto Alegre
Contact	Hugo G Oliveira, PhD
Phone	+55 51 3359-8241
Email	hugo@hugooliveira.org
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	November 19, 2019
Completion date	April 30, 2029

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03923660` - Ventilatory Adaptation to Concentric Versus Eccentric Exercise in Patients With Severe COPD	N/A
Not yet recruiting	`NCT06008210` - A Decision Aid on End-of-life Care for Patients With Advanced COPD and Their Family	N/A
Recruiting	`NCT05029349` - Exploration of the VOLATOLOM in the Stable Severe COPD (Chronic Obstructive Pulmonary Disease)	N/A
Not yet recruiting	`NCT05539547` - Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD	Early Phase 1
Suspended	`NCT04848012` - Efficacy of an Advanced Auto-titrating NIV in COPD	N/A
Recruiting	`NCT06198309` - Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease
Recruiting	`NCT03398772` - Effects of a Comprehensive Health Coaching Program in Advanced Chronic Obstructive Pulmonary Disease.	N/A
Completed	`NCT05259280` - Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD	N/A
Not yet recruiting	`NCT06212765` - Oral Citrulline Supplementation in COPD Patients With Malnutrition	Phase 3
Completed	`NCT02962999` - Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation	Phase 4
Not yet recruiting	`NCT06229509` - Study of the Cytokine Response During Exercise Dyspnea in Patients With Chronic Obstructive Pulmonary Disease (COPD). Effect of Body Composition	N/A
Completed	`NCT05431218` - Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD	Phase 4
Recruiting	`NCT04069312` - Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)	Phase 3
Recruiting	`NCT05575336` - Assessment of the Effectiveness, Socio-economic Impact and Implementation of a Digital Solution for Severe Patients	N/A
Completed	`NCT02998515` - Effects of Different Oxygen Devices in Hypoxemic COPD Patients	N/A
Completed	`NCT04533516` - Additional Manual Therapy Over Inspiratory Muscle Training in COPD	N/A
Not yet recruiting	`NCT06247397` - Effect of HIgh-flow Therapy in Long-term Oxygen Therapy	N/A
Recruiting	`NCT06072690` - Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cell Therapy Associated With Endobronchial Valve — CEL&VAL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms